Brokerages Set EIKN (NASDAQ:EIKN) Target Price at $25.60

EIKN (NASDAQ:EIKN) has been given an average recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $25.60.

A number of brokerages have recently commented on EIKN. Wall Street Zen cut shares of EIKN from a “hold” rating to a “sell” rating in a research note on Sunday, April 5th. Wedbush reaffirmed an “underperform” rating and set a $7.00 price objective on shares of EIKN in a research note on Tuesday, March 31st. JPMorgan Chase & Co. began coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “overweight” rating and a $29.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of EIKN in a research note on Monday, March 2nd. They set an “overweight” rating on the stock. Finally, Bank of America began coverage on shares of EIKN in a research note on Monday, March 2nd. They set a “buy” rating and a $34.00 price objective on the stock.

EIKN Stock Performance

Shares of NASDAQ:EIKN opened at $10.70 on Tuesday. EIKN has a twelve month low of $8.58 and a twelve month high of $17.40. The stock has a 50 day simple moving average of $12.12.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.